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Abstract
Background: Anoectochilus formosanus has been used as a Chinese folk medicine and is known as the “King of
medicine” in Chinese society due to its versatile pharmacological effects such as anti-hypertension, anti-diabetes,
anti-heart disease, anti-lung and liver diseases, anti-nephritis and anti-Rheumatoid arthritis. Kinsenoside is an
essential and active compound of A. formosanus (Orchidaceae). However, the anti-arthritic activity of kinsenoside
has still not been demonstrated. In the present study, we confirmed that the kinsenoside treatment rheumatoid
arthritis induced by collagen-induced arthritis in mice.
Methods: Male DBA/1 J mice were immunized by intradermal injection of 100 μg of type II collagen in CFA.
Kinsenoside was administered orally at a dose of 100 and 300 mg/kg once a day after 2nd booster injection. Paw
swelling, arthritic score and histological change were measured. ELISA was used to measure cytokines including
tumor necrosis factor alpha (TNF-α), interleukin-10 (IL-10), interleukin-17 (IL-17) and interferon-γ (IFN-γ) in the
splenocyte according to the manufacturer’s instructions.
Results: Compared with model group, kinsenoside significantly inhibited paw edema and decreased the arthritis
score and disease incidence. Histopathological examination demonstrated that kinsenoside effectively protected
bone and cartilage of knee joint from erosion, lesion and deformation versus those from the CIA group.
Kinsenoside also decreased IL-1β, TNF-α, and MMP-9 expression, and increased the expression of IL-10 in inflamed
joints. The administration of kinsenoside significantly suppressed levels of TNF-α, IFN-γ, and IL-17, but increased
concentrations of IL-10 in the supernatants of each of the splenocytes in CIA mice compared with that in the H2O-
treated mice with CIA. Using flow cytometric analysis, we demonstrated that kinsenoside increases the population
of CD4+CD25+ regulatory T cells, thereby inhibiting the Th1 cell and B cell populations. Anticollagen IgG1 and
IgG2a levels decreased in the serum of kinsenoside-treated mice.
Conclusions: These results suggest that the administration of kinsenoside effectively suppressed inflammatory
mediators’ production and bone erosion in mice with collagen-induced arthritis showing the potential as an anti-
arthritis agent.
Keywords: CIA, Kinsenoside, Rheumatoid arthritis, Inflammation
* Correspondence: wclin@mail.cmu.edu.tw
3School of Pharmacy, China Medical University, Taiwan. 91 Hsueh Shih Road,
Taichung 404, Taiwan, ROC
Full list of author information is available at the end of the article
© 2016 Hsiao et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Hsiao et al. BMC Complementary and Alternative Medicine  (2016) 16:80 
DOI 10.1186/s12906-016-1054-8
Background
Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease, characterized by the occurrence of inflammatory
synovitis, which leads to the destruction of cartilage and
bone within joints through inflammatory cells that migrate
to the synovial and periarticular tissues [1]. In states of
chronic inflammation, such as in RA, the imbalance be-
tween proinflammatory and antiinflammatory cytokines de-
termines the degree and extent of inflammation causing
cellular damage [2]. Proinflammatory cytokines, including
TNF-α, IL-17, IL-6, and IFN-γ, are the main mediators that
initiate and cause inflammation to persist in RA, whereas
antiinflammatory cytokines such as IL-4 and IL-10 can in-
hibit these processes [3]. Researchers have hypothesized
that early inflammatory T cells, such as Th1 cells, play a
critical role in the development of RA [1], and that Th1
cells (except for Th17 cells) are predominant in the joints
of patients with RA, whereas Th2 cells, which suppress
antigen-specific immune responses, are decreased [4]. Re-
cently, the focus of research has expanded from Th1 and
Th2 cells to regulatory T cells (Tregs), which can maintain
immune homeostasis [5]. Current treatment modalities for
RA either provide symptomatic relief (nonsteroidal antiin-
flammatory drugs; NSAIDs) or modify the disease process
(disease-modifying antirheumatic drugs; DMARDs). Ac-
cording to the guidelines of the American College of
Rheumatology, patients with newly diagnosed RA are
strongly recommended to begin dual treatment by using
NSAIDs to relieve nociceptive pain and control inflamma-
tion, and DMARDs to reduce disease activity, prevent joint
deformity, and improve joint function [6]. The administra-
tion of these drugs is limited by the severe adverse effects
of the drugs, such as gastrointestinal lesions, cardiovascular
complications, and reproductive toxicity [7]. Therefore,
researchers are focusing increasingly on plant-derived anti-
RA drugs with high efficacy and few side effects. Recent
studies have estimated that 60–90 % of patients with RA
are highly likely to use botanical products [8]. This growing
interest in alternative medical practices clearly indicates the
necessity for more safe and effective anti-RA botanicals
used in traditional medicine.
Anoectochilus formosanus has been used as a Chinese
folk medicine and is known as the “King of medicine” in
Chinese society due to its versatile pharmacological effects
such as anti-hypertension, anti-diabetes, anti-heart disease,
anti-lung and liver diseases, anti-nephritis and anti-
Rheumatoid arthritis [9]. Therefore, A. formosanus extract
is often used as a health supplement in Taiwan. Kinsenoside
[3-(R)-β-D-glucopyranosyloxybutanolide] is an essential
and active compound of A. formosanus (Orchidaceae) [10].
In previous studies, we discovered that kinsenoside amelio-
rated lipopolysaccharide (LPS)-induced shock in mice, and
carbon tetrachloride caused hepatitis in mice by inhibiting
macrophage activation [11, 12]. Kinsenoside significantly
inhibited the LPS-induced production of nitric oxide in
both peritoneal lavage macrophages and RAW 264.7 cells
in mice by suppressing NF-κB activation [11]. In addition,
we discovered that a standardized aqueous extract of A. for-
mosanus modulated Tregs, thereby increasing the immuno-
suppression of airway hyperresponsiveness in mice that
inhaled ovalbumin [13]. Therefore, kinsenoside may be able
to downregulate both autoimmune and inflammatory
responses in mice with collagen-induced arthritis (CIA). Al-
though as far as we know, no studies have focused on the
in vivo effects of kinsenoside. We encourage researchers to
evaluate the anti-arthritic effects of kinsenoside in future
studies.
In this study, we evaluated the immunomodulatory role
of Tregs following the administration of kinsenoside during
the initiation and establishment of arthritis in mice with
CIA. Furthermore, we discussed the immunomodulatory
role of Tregs following the administration of kinsenoside in
proinflammatory cytokine release, and the resulting de-
crease in matrix metalloproteinases (MMP)-9 expression.
Methods
Animals
Male DBA/1 J mice were obtained from the Jackson
Laboratory (Bar Harbor, Maine, USA), and were housed
in standard laboratory cages and allowed access to tap
water ad libitum. The experimental animals were housed
in an air-conditioned room at 22–25 °C under a 12 h
light–dark cycle. All animals were treated in accordance
with the Institutional Animal Care and Use Committee
(IACUC) of China Medical University, and the study
protocol was approved by the ethics committee of the
China Medical University, Taichung, Taiwan.
Preparation of kinsenoside
Kinsenoside was prepared by Associate Professor Wu.
Fresh whole plants of A. formosanus (10 kg) were ex-
tracted with water and the filtrate was partitioned succes-
sively with ethyl acetate. Water-soluble portions (AFEW)
were evaporated under reduced pressure, yielding 218.4 g
of red residue. AFEW (210 g) was applied to a DIAION
HP-20 column (Nippon Ressui Co., Japan) and eluted with
H2O, 10, 20, and 50 % methanol in water, and 100 %
methanol to provide five fractions (AFEW-1–AFEW-5).
The dry weight of fraction AFEW-2 was 22.1 g. Fraction
AFEW-2 (10 g) was further purified using silica gel (Si
60 F245; Merck, Germany) with chloroform/ethanol
(15:8) as the mobile phase to provide four fractions. Frac-
tion 4 (4.5 g) was applied to preparative high-performance
liquid chromatography (HPLC) to yield a pure compound
(4.1 g). Conditions used for the preparation of HPLC were
as follows: pump, Shimadzu LC-8A (Kyoto, Japan); mobile
phase, water; column, Mightysil ODS RP-18 Aqua column
(i.d. 20 mm, 250 mm long; 5 μm particle size; Kanto
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Chemical Co., Tokyo, Japan). The pure compound was
identified by mass spectroscopy (Jeol GCmate, Tokyo,
Japan). The content of kinsenoside was measured using
HPLC. The conditions of HPLC were the same as those
described in a previous study [14]. The identity and purity
of the kinsenoside (>85 %) was analyzed using high-
performance liquid chromatography based on a previous
study [14].
Induction and assessment of collagen-induced arthritis
CIA is typically induced using intradermal immunization
with type II collagen (CII) in Freund’s complete adjuvant
(CFA, Sigma-Aldrich, St. Louis, MO, USA), followed by an
intradermal booster immunization after 21 days [15]. In
brief, CII purchased from Sigma-Aldrich (St. Louis, MO,
USA) was reconstituted at 2 mg/ml in 50 mM acetic acid.
Mice received an intradermal injection of 100 μg of CII in
CFA (Day 0, primary immunization), and a booster injec-
tion of 100 μg of CII in Freund’s incomplete adjuvant
(Sigma-Aldrich, St. Louis, MO, USA) on Day 21 (2nd
booster injection). Following a prophylactic dosing pro-
gram, the animals were randomly divided into four experi-
mental groups, each containing six individuals, and treated
follows:
Naive: no treat, normal.
CIA control: H2O 1 ml/kg p.o.
CIA+ kinsenoside 100 mg/kg: kinsenoside 100 mg/kg
p.o.
CIA+ kinsenoside 300 mg/kg: kinsenoside 300 mg/kg
p.o.
The mice were orally administered kinsenoside (100 or
300 mg/kg in water) daily, from Day 1 to Day 21 after 2nd
booster injection, and monitored for disease incidence
and severity up to Day 21. The CIA control mice were ad-
ministered water alone.
Arthritic severity scores were derived as follows: The
clinical scores for paws were used to reflect the severity of
arthritis, and were classified as 0 (normal joints), 1 (swell-
ing in one digit or joint inflammation), 2 (swelling in two
or three digits, or slight paw swelling), 3 (swelling in more
than four digits and moderate swelling in the entire paw),
and 4 (severe swelling and deformation of the paw, also
presenting rigid joints); the sum of the scores of all four
paws of each mouse represented the total clinical score.
Cumulative disease scores were calculated by adding the
daily disease scores from the day following immunization
onward, until the end of the experiment. The incidence of
arthritic paws was defined as the occurrence of inflamed
paws with a clinical arthritis score of 2 or higher among
four paws.
On Day 21, all of the mice were anesthetized and blood
was collected using cardiac puncture; the mice were then
sacrificed using cervical dislocation after 2nd booster in-
jection. The mice spleens were removed and used for
enzyme-linked immunosorbent assay (ELISA) analysis,
total cell count, flow-cytometric analysis, and histological
and histochemical examinations.
Identification of anticollagen antibodies in serum
Identification of anticollagen antibodies in serum
followed according to the procedure of Poosarla et al.
(2011) [16]. Serum collected at the end of the experi-
ment was stored at − 80 °C. The level of anti-CII anti-
bodies was measured using ELISA analysis. In brief,
200 μl/well of CII (10 μg/ml) in phosphate-buffered sa-
line (PBS) was coated on plates at 4 °C, and left to
stand overnight. After washing, the plates were treated
with blocking buffer solution (50 mM Tris, 0.14 M NaCl,
1 % BSA, pH 8.0) for 30 min. After washing the plates,
the samples (100 μl/well) were incubated for 90 min at
room temperature. After washing the plates,, the plates
were incubated with horseradish-peroxidase (HRP)-conju-
gated goat antimouse IgG1, or IgG2a (Bethyl Laboratories,
Inc., Montgomery, TX, USA) for 60 min. After washing,
the plates were placed in tetramethylbenzidine (TMB;
Kirkegaard & Perry Laboratories, Gaithersburg, MD, USA)
substrate solution, and incubated at room temperature for
30 min. The enzymatic reaction was terminated by adding
50 μl of stop solution (2 M H2SO4), and the absorbance of
each well was measured at 450 nm (TRIAD multimode
reader, Dynex Technologies, Sullyfield Circle, USA).
CII-induced cytokine production
Splenocytes were collected from all groups, both with
and without CIA immunization (n = 6 for all groups)
on Day 21 of the prophylactic protocol, and seeded
with 1 × 106 cells/well in RPMI-1640 supplemented
with 10 % FBS, and cultured for 48 h with or without
5.0 μg/ml Con A (Sigma-Aldrich St. Louis, MO, USA)
in 24-well plates. Supernatants were collected and
stored at − 80 °C. Cytkine concentrations, including
TNF-α, IFN-γ, IL-10 (eBioscience, San Diego, CA,
USA), and IL-17 (R&D Systems Inc., Minneapolis,
MN, USA), were measured using by ELISA according
to the manufacturer’s protocol
Gene expression analysis
RNA was extracted from the left hind paws of the mice,
snap-frozen in liquid nitrogen, ground into powder, and
homogenized. This procedure was conducted under
RNase-free conditions. Total RNA was extracted from the
tissue homogenates by using TRIzol (Invitrogen; Carlsbad,
CA, USA) according to the manufacturer instructions. The
total RNA (3 μg) was subjected to room temperature reac-
tion by using Moloney murine leukemia virus reverse tran-
scriptase (M-MuLV, Hopegen Biotechnology, Taichung,
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Taiwan, ROC) according to the directions in the instruction
manual. The specific primers are listed in Table 1. The
cDNA was amplified with a combination of sense and
antisense primer pairs and PCR master mix (Fermentas
International Inc., Burlington, Canada) by using a ther-
mal cycler (Astec, Tokyo, Japan).
Flow cytometric analysis
Splenocytes were collected for analysis by using flow
cytometry. Single-cell suspensions, both with and without
CIA, were identified by detecting surface markers with
the specific binding of monoclonal antibodies (mAb).
In brief, 50 μl of cell suspension (5 × 105 cells) was in-
cubated in the presence of saturating concentrations
of fluorescein-, phycoerythrin-, or PE-Cy5-conjugated
mAb (eBioscience, San Diego, CA., USA) on ice for
30 min in darkness. Cytofluorometric analysis of the
lymphocyte fractions was performed using side scatter
and forward scatter with laser excitation at 488 nm.
Flow cytometric data acquisition and analysis of cell
populations of at least 1 × 104 leukocytes were per-
formed on a CellQuest computer system (BD Biosci-
ences). Percentage list mode data were calculated
based on the number of lymphocytes identified in each
quadrant. B cells were determined using the surface
markers CD19+ (clone MB19-1) and CD45+ (clone 30-
F11), T helper 1 (Th1) cells were determined using
CD4+ (clone RM4–5) and Tim-3+ (clone 8B.2C12),
and Tregs were determined using CD4+ and CD25+
(clone 7D4).
Histological and histochemical examination
On Day 21, the left hind paws of the H2O-treated
group, the kinsenoside-treated group, and the con-
trol group were fixed in 10 % neutral phosphate-
buffered formalin. These specimens were decalcified
in 10 % EDTA for 2 weeks, embedded in paraffin,
and sectioned at 5-μm intervals. Hematoxylin and
eosin staining, tartrate-resistant acid phosphatase
(TRAP) staining, and immunohistochemical staining
were performed by following standard methods. For
the TRAP assay of osteoclast activity, samples were
embedded in paraffin and prepared for TRAP stain-
ing. After washing with distilled water, samples were
incubated for 60 min at 37 °C in darkness in a solu-
tion containing Fast Garnet GBC, sodium nitrite,
napthol AS-BI phosphoric acid, acetate, and tartrate,
which was made using a Leukocyte Acid Phosphatase
Assay kit (Sigma-Aldrich, St. Louis, MO). The sam-
ples were washed with water, and TRAP-positive
multinucleated cells, containing three or more nu-
clei, were counted under a microscope. For immuno-
histochemical staining, the cryostat section of joints
was fixed in cold acetone for 10 min, washed in
PBS, and treated with 0.3 % H2O2 in absolute metha-
nol for 15 min to deplete endogenous peroxidase. After
blocking nonspecific binding by using 10 % nonfat milk in
PBS for 30 min, the sections were incubated with antirabbit
MMP-9 Ab (Millipore, MA, USA) or CD 68+ Ab (Abcam,
Cambridge, UK) at appropriate dilutions for 1 h at room
temperature, washed, incubated with biotinylated antirabbit
IgG, washed and incubated with avidin-biotinylated HRP
complex and diaminobenzidine tetrahydrochloride (Elite
kit; Vector Laboratories Inc., Burlingame, CA, USA), and
counterstained with Mayer’s hematoxylin.
Splenocyte preparation and CD4+ T cell isolation
Splenocytes were prepared by disrupting the spleen
between glass slides in complete medium (RPMI 1640
with 10 % FBS and 1 % PSA). After 10 min of centrifuga-
tion at 300 × g to separate cells from debris, the cells were
washed in RPMI medium, followed by the lysis of erythro-
cytes by using 0.1X HBSS and 2X HBSS. Splenic CD4+
cells were purified using flow cytometry (BD FACSAria) to
perform positive selection with CD4+ (eBioscience, San
Diego, CA., USA). The purity was >95 %.
In vitro Th1 and Th2 cell polarization
CD4+ T cells (1 × 106 cells/well) were resuspended in
complete medium (RPMI 1640 with 10 % FBS and 1 %
PSA) and activated with plate-bound 6 μg/ml anti-CD3
(BioLegend, San Diego, CA) and 6 μg/ml anti-CD28
(BioLegend, San Diego, CA) for 24 h. Naive CD4+ T cells
were incubated with 20 ng/ml rIL-12 (BioLegend, San
Diego, CA), 20 μg/ml anti-IL-4 (BioLegend, San Diego,
Table 1 PCR primers
Gene name primers bp cycle (°C)
IL-10 F:CCCTTTGCTATGGTGTCCTT 97 35 50
R:TGGTTTCTCTTCCCAAGACC
IL-1β F:TTCAAGGGGACATTAGGCAG 158 35 51
R:TGTGCTGGTGCTTCATTCAT
TNF-α F:CTCAGCGAGGACAGCAAGG 108 35 53
R:AGGGACAGAACCTGCCTGG
MCP-1 F:AGAGAGCCAGACGGGAGGAA 190 35 56
R:GTAGCAGCAGGTGAGTGGGG
MMP-9 F:GGTCTAGGCCCAGAGGTA 310 35 57
R:GGTCGTAGGTCACGTAGC
T-bet F:TTCAACCAGCACCAGACAGA 109 35 62
R:ACATCCTGTAATGGCTTGTGG
GATA-3 F:TTCAAGGGGACATTAGGCAG 78 35 60
R:TGGTGGTGGTCTGACAGTTC
GAPDH F:CTTCATTGACCTCAACTACATGGTCTA 99 35 55
R: GATGA CAAGC TTCCC ATTCT CAG
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CA), and 20 ng/ml rIL-2 (ProSpec-Tany TechnoGene
Ltd., Rehovot Science Park, Israel) for Th1 differenti-
ation. For Th2 cell differentiation, 20 μg/ml IL-4 (Pro-
Spec-Tany TechnoGene Ltd., Rehovot Science Park,
Israel) and 10 ng/ml rIL-2 (ProSpec-Tany TechnoGene
Ltd., Rehovot Science Park, Israel) were added to the
culture medium in the presence of 20 ng/ml rIL-2. Cells
were cultured for 7 days and harvested for the prepar-
ation of total RNA.
Statistical analysis
Results are expressed as the mean ± standard deviation
[17]. All experimental data were analyzed using one-way
analysis of variance following the Dunnett test. P < 0.05 was
considered statistically significant. The Mann—Whitney U
test was used to determine the severity scores of the kinse-
noside group and the H2O-treated CIA group, and the
scores were expressed as the mean ± SD for each group at
each time point. P < 0.05 was considered statistically
significant.
Results
Effects of kinsenoside on mice with collagen-induced
arthritis
We used a mouse CIA model to determine whether kin-
senoside exerts suppressive effects on RA. Kinsenoside
administered daily significantly suppressed CIA in mice
in a dose-dependent manner. Mice treated with 100 and
300 mg/kg of kinsenoside exhibited significant reduc-
tions in incidence and severity of CIA (Fig. 1a). On Day
10, arthritis incidence and mean severity score for the
group treated with 300 mg/kg of kinsenoside were 3.6 ±
0.5, respectively, as opposed to 6.6 ± 1.3 for the H2O-
treated group. This treatment significantly reduced arth-
ritis severity scores on 0–20 day and arthritis scores and
disease incidence attained their maxima after 2nd
booster injection in all mouse groups (Fig. 1b and c).
Effects of kinsenoside on joint histology
To investigate the effects of kinsenoside on the pro-
gression of CIA, the oral administration of kinsenoside
`
Fig. 1 The effects of kinsenoside on the development and clinical of CIA. a Photograph type (hind paw volume). (b). Clinical scores of CIA were
monitored every 5 day after booster immunization. (c)The incidence of arthritic paws overtime was monitored. (*p < 0.05 vs. H2O-treated group,
n = 6 in each group)
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(100 and 300 mg/kg) was initiated 1 day after 2nd
booster injection. After sacrificing the mice, we evaluated
the histology of the synovial tissues. Figure 2a illustrates
that kinsenoside inhibited cartilage and bone destruction,
as well as inflammatory responses in the treated group,
compared with that in the H2O-treated CIA group. The
treatment of mice with CIA by using kinsenoside resulted
in significant reductions in cellular infiltration, pannus for-
mation, and the destruction of cartilage and bone in arth-
ritic joints, with low pathogenic scores.
TRAP+ osteoclasts (red staining) were present on
the bone surfaces of the mice with CIA not treated
with kinsenoside, particularly around the navicular
bone. In the kinsenoside-treated mice, however, the
accumulation of TRAP+ cells was significantly less
than that in the mice not treated with kinsenoside,
and navicular bone structure was maintained (Fig. 2b).
Immunohistochemical staining of synovial tissues in the
H2O-treated CIA group revealed high levels of MMP-9
and CD68+ expression. By contrast, mice with CIA treated
with kinsenoside exhibited significant reductions in
MMP-9 and CD68+ expression (Fig. 2c and d).
Kinsenoside inhibits inflammatory cytokines and MMP-9
expression in the joints of mice with collagen-induced
arthritis
Local and circulating cytokine levels were measured in
the joint tissues and sera to obtain insight into the
mechanisms of beneficial kinsenoside-mediated ef-
fects. In Fig. 3, the reverse-transcription polymerase
chain reaction (RT-PCR) results indicated the pres-
ence of relatively small amounts of IL-1β, TNF-α, and
MMP-9 mRNA in the joints of healthy mice. However,
the concentrations of these transcripts exhibited a
substantial increase in the joints of the mice with CIA.
Kinsenoside treatment significantly reduced elevated
levels of IL-1β, TNF-γ and MMP-9. By contrast, the
expression of IL-10 in the joints of mice with CIA was
significantly lower than that of healthy mice (Fig. 3),
and the administration of 300 mg/kg of kinsenoside in-
creased IL-10 gene expression to levels comparable with
those of the H2O-treated group. These results suggested
that kinsenoside prevented the destruction of connective
tissues by simultaneously augmenting IL-10 production
and reducing IL-1β, TNF-α, and MMP-9 production at in-
flammatory sites in mice with RA.
Kinsenoside downregulates proinflammatory cytokine
production
We performed in vitro assay of CIA-induced cytokine
production by mouse splenocytes to clarify whether
kinsenoside treatment regulates cytokine production.
Equivalent numbers of splenocytes from the H2O-
treated and kinsenoside-treated mice with CIA were
cultured with Con A. We measured the production of
Th1-related cytokines (IFN-γ), Th2-related cytokines
Fig. 2 Pathologic morphology of the knee joints following administration of kinsenoside to mice after the onset of CIA. H&E staining a TRAP (b)
and immunohistochemical staining MMP-9 (c) and CD 68+ (d) sections of the synovial tissues from mice with Naïve and CIA treated with H2O
and kinsenoside. Original magnification × 200
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(IL-10), Th17-related cytokines (IL-17), and proin-
flammatory cytokines (TNF-α) in the supernatants of
each splenocyte culture. We discovered that the levels
of IFN-γ, IL-17, and TNF-α were significantly sup-
pressed in the supernatants of each of the splenocyte
cultures of kinsenoside-treated mice with CIA, com-
pared with that in the H2O-treated mouse group
(Fig. 4a, b, and c).
However, the levels of IL-10 in the splenocytes of the
kinsenoside-treated mice were significantly increased
compared with that in the H2O-treated mice (Fig. 4d).
These data indicated that kinsenoside suppressed Con A-
induced cytokine production (IFN-γ, IL-17 and TNF-α) in
the supernatants of each of the splenocyte cultures during
the progression of arthritis.
Fluorescence-activated cell sorting analysis of splenocytes
We investigated the recruitment of total cells in
splenocytes, and measured the effects of kinsenoside
on inflammatory cells to evaluate the effects of
Fig. 3 Effects of kinsenoside on mRNA expression of the inflammatory cytokines, MMP-9 and MCP-1 in the joints of CIA mice. Fragments were
amplified by RT-PCR (a). The expression levels of IL-1β, TNF-α, IL-10, MMP-9 and mRNA were measured and quantified densitometrically (b). The
mice were treated as described in the Materials and methods section. Values were expressed as means ± SD, n = 6 in each group. # P < 0.05, ## P
< 0.01 as compared with the naïve group. * P < 0.05, ** P < 0.01 as compared with the H2O-treated group
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kinsenoside on mice with CIA. The cell population of
the splenocytes in the kinsenoside-treated group ex-
hibited a decrease, compared with that in the H2O-
treated controls (Table 2). Fluorescence-activated cell
sorting analysis of CD4+, CD19+, CD25+, CD45+, and
Tim-3+ cell populations, in both healthy mice and
those with RA, revealed that the population of Th1
cells produced by CD4+Tim-3+ cells was higher in the
splenocytes of the H2O-treated group than in those of
the other groups. The CD19+CD45+ B cell population
exhibited an increase in the H2O-treated group, but not in
the kinsenoside-treated mice with CIA (Table 2). The Th1
cell population was lower in the kinsenoside-treated CIA
group splenocytes (300 mg/kg) than in the H2O-treated
group (Table 2). The population of Tregs among total
CD4+CD25+ cells in the H2O-treated CIA group was
Fig. 4 Inhibitory effect of kinsenoside on CII-induced cytokine production by splenocytes in vitro. Splenocytes from normal control or CIA mice
were cultured for 48 h with or without 50 μg/ml Con A. The supernatants were collected, and the IFN-γ a IL-17 (b), TNF-α (c) and IL-10 (d) levels
were measured. Values were expressed as means ± SD, n = 6 in each group. # P < 0.05, ## P < 0.01 as compared with the naïve group. * P < 0.05,
** P < 0.01 as compared with the H2O-treated group
Table 2 Effect of kinsenoside on the splenocytes in vivo
The splenocytes (%) Control H2O Kinsenoside 100 mg/kg Kinsenoside 300 mg/kg
CD4+Tim-3+ cells 4.96 ± 0.63 9.12 ± 0.79 ## 7.62 ± 0.93** 7.04 ± 0.74**
CD4+CD25+ cells 8.31 ± 0.48 6.21 ± 0.82 ## 7.82 ± 0.91** 8.26 ± 0.78**
CD19+CD45+ cells 26.99 ± 4.56 36.2 ± 2.52 ## 25.84 ± 5.64** 23.75 ± 3.98**
Population of the splenocytes in normal control and CIA mice. The cell populations of the CD4+Tim-3+, CD4+CD25+ and CD19+CD45+ cells in the splenocytes.
Values were expressed as means ± SD, n = 6 in each group. ## P < 0.01 as compared with the control group. **P < 0.01 as compared with the H2O-treated group
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lower than that in the control group, but higher than that
in the kinsenoside-treated groups (Table 2).
Kinsenoside downregulates Ag-specific B cell responses
We assessed the levels of CII-specific IgG1 and IgG2a
antibodies, and the kinsenoside-treated group exhibited
downregulation of anti-CIA IgG1 and IgG2a antibody
production (Fig. 5).
Effects of kinsenoside on the modulation of Th1/Th2 cell
polarization
We investigated whether kinsenoside would produce a
similar effect under Th1- and Th2-polarized conditions.
CD4+ T cells were activated using anti-CD3/anti-CD28
and cultured in kinsenoside-containing medium under
Th1-inducing or Th2-inducing conditions. To investigate
the direct effect of kinsenoside on Th1- and Th2-specific
cytokine gene expression, we performed real-time RT-
PCR by using RNA from activated CD4+ T cells. Our data
(Fig. 6) indicated that kinsenoside did not affect T-bet ex-
pression in the Th1-polarized culture, or GATA-3 expres-
sion in the Th2-polarized culture.
Discussion
In this study, we demonstrated the antiinflammatory
and antiarthritic effects of kinsenoside on mice with
CIA, which were used as an experimental model of RA.
We performed this study to elucidate the effects and
modulation of kinsenoside on a CIA model. In the CIA-
induced animal model, kinsenoside improved the sever-
ity of arthritis, inhibited the progression of CIA, and
increased IL-10 levels. Kinsenoside markedly inhibited
clinical signs of joint swelling, and significantly reduced
inflammatory cell infiltration and bone erosion. These
results indicated that kinsenoside exerts a distinct pre-
ventive effect on CIA.
Fig. 5 Effects of kinsenoside on anti-CII IgG1 and IgG2a. Serum was obtained from 6 mice of each group on day 21 after the booster injection.
Values were expressed as means ± SD, n = 6 in each group. #P < 0.05, ##P < 0.01 as compared with the naïve group. *P < 0.05, **P < 0.01as compared
with the H2O-treated group
Fig. 6 The effect of kinsenoside on helper T-cell differentiation in Th1 or Th2 polarized conditions. Th0 cells (CD4+) were sorted by FACSAria for
RT-PCR analysis. FACSAria (BD Biosciences) was used to sort Splenic CD4+ cellswith the purity of >95% (a). Gene expression was measured by RT-
PCR for T-bet (b), GATA-3 (c) in polarized splenocytes and compared with non-stimulated splenocytes (day 7). RT-PCR data were normalized to
GAPDH expression and presented as means ± SD, n = 3 in each group. ##P < 0.01as compared with the vehicle group
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CIA has been widely used as an animal model in RA re-
search. It is a chronic inflammatory disease characterized
by infiltration of the synovial membrane and is associated
with the destruction of joints. In addition, CIA more
closely resembles human RA in clinical, histological, and
immunological features, as well as genetic linkage than do
other experimental arthritis models [18]. Therefore, paw
swelling and arthritis scores were used to measure the an-
tiarthritic effects of various drugs on the development of
the chronic inflammation of CIA. We demonstrated that
the oral administration of kinsenoside produced a strong
antiarthritic effect capable of reducing CIA paw edema
and swelling, which was indicated by the arthritis score.
RA-induced inflammation mainly occurs in the synovium
and joints, which can be intuitively deduced from the re-
sults of histopathological assays. Histologically, we ob-
served significant attenuation in the cellular infiltration of
the synovium, synovial hyperplasia, and cartilage damage
in mice treated with kinsenoside. In a previous study, in-
flammatory cytokines induced cell infiltration in joints
and increased osteoclast differentiation from monocytes
to attenuate disease progression and joint destruction
[19]. Hsiao et al. discovered that kinsenoside suppressed
osteoclastogenesis [20]. Histological analysis of the joint
area of mice with CIA revealed that kinsenoside treatment
markedly inhibited the infiltration of inflammatory cells,
including numerous TRAP+ cells (osteoclasts), as well as
severe osteolytic bone destruction associated with arthritic
inflammation. Kinsenoside also decreased the expression
of MMP-9 and CD 68+ cells (macrophages) in inflamed
joints. Thus, our research demonstrated that kinsenoside
could protect affected joints against cartilage destruction
and bone erosion, and reduced cellular infiltration and
synovial hyperplasia in joints.
Chronic inflammation involves the release of several
mediators that are responsible for pain, as well as the
destruction of bone and cartilage that can lead to severe
disability [21]. However, macrophages, the major effec-
tors of synovitis, operate through cytokine secretion,
which includes TNF-α, IL-1β, and IL-6 [22]. Macro-
phages influence joint inflammation and the destruction
of cartilage and bone in patients with RA [23], which
can regulate the production of proinflammatory cyto-
kines, including IL-1β and IL-6 in vitro [24], and stimu-
late inflammatory cells to secrete MCP-1 and produce
MMP-9 [2]. A recent study reported that at the site of
joint inflammation, the level of MCP-1 is increased in
the blood, synovial fluid, and synovial tissue of patients
with RA and OA, primarily by monocytes and lympho-
cytes [25]. The role of MCP-1 in an inflamed RA joint
may be the recruitment of mononuclear phagocytes.
Cytokine and chemokine are responsible for the migra-
tion and accumulation of leukocytes at inflammatory
sites. MMP-9 plays a crucial role in the migration of
macrophages in RA [26]. Upregulating the production of
MMP-9 could degrade the cartilage matrix by stimulat-
ing proinflammatory cytokines [27]. Researchers have
recognized that MMP-9 plays an essential role in the
degradation of connective tissue components in the
cartilage of patients with RA. The expression and pro-
duction of MMP-9 is regulated at the transcriptional
level by proinflammatory cytokines [28]. A reduction in
disease severity and bone resorption could be caused by
the blockage of these molecules [29], whereas IL-4 and
IL-10 possess potent antiinflammatory characteristics
and can suppress cartilage and bone pathology in
patients with RA [30]. In the present study, we demon-
strated that kinsenoside significantly decreased the CIA-
augmented gene expression of TNF-α, IL-1β, MMP-9,
and MCP-1, and increased the gene expression of IL-10
in the inflamed joints of mice with CIA. Our previous
study, which demonstrated that LPS-induced gene ex-
pression of TNF-α, IL-1β and MCP-1 is inhibited and
the gene expression of IL-10 is enhanced by kinsenoside
in macrophages, supports these results. Therefore, we
concluded that kinsenoside can suppress cartilage deg-
radation in the inflamed joints of patients with RA.
Recent studies have demonstrated that numerous RA
patients exhibit changes in morphology and inflammatory
phenotypes in synovial tissue, characterized histologically
by hypertrophy and the infiltration of leucocytes and mono-
cytes or macrophages [31]. CIA has provided scientists with
a translational model that defines the role of inflammatory
cytokines in RA, particularly TNF-α, IL-1β, and IL-17 [32].
Therefore, RA therapy is expected to rapidly control in-
flammation, suppress progressive joint destruction, and be
safe to use. A previous study by Hsiao et al. [11] reported
that kinsenoside could effectively suppress macrophages, a
critical pathway for driving proinflammatory cytokine pro-
duction. Our results indicated that the administration of
kinsenoside to mice with CIA inhibited IFN-γ and TNF-α
production and increased IL-10 production in splenocytes
by stimulating Con A production. The expression of IL-17,
induced mainly by Th17 cells, in the synovium has been
associated with the disease severity of RA [33]. IL-17 in-
creases the activation of synoviocytes and expression of
other cytokines, thereby contributing to cartilage and bone
destruction [34]. In patients with RA and in CIA models,
IL-17 was detected at increased levels in joints, and ele-
vated levels of IL-17A were observed in the inflamed syno-
vium [35]. In this study, the administration of kinsenoside
to CIA mice inhibited the secretion of IL-17, suggesting
that the antiinflammatory action of kinsenoside is associ-
ated with a significant reduction in the release of IL-17.
Thus, kinsenoside downregulated the production of the
proinflammatory cytokines TNF-α, IFN-γ and IL-17 in the
splenocytes, and increased the levels of antiinflammatory
cytokine IL-10, which ameliorated the disease.
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In the past, scientists have asserted that RA is a Th1-
associated disorder [36], and considered Th1 cells to be
the principal T-cell players in the pathogenesis of RA.
One previous study reported that Th1 cells were observed
in the joints of patients with RA [37]. Tregs from healthy
individuals or patients with RA receiving treatment sup-
pressed the proliferation of responder T cells and reduced
IFN-γ production [38]. Additionally, one study reported
that Tregs isolated from the synovial fluid or peripheral
blood of patients with RA suppressed the proliferation of
autologous T cells in vitro [39]. Therefore, Tregs suppress
the proliferation and cytokine production of CD4 T cells
through the inhibition of IL-2 transcription. Furthermore,
Tregs are crucial for the suppression of potentially harm-
ful excessive immune responses [5]. However, kinsenoside
would produce a similar effect under Th1- and Th2- po-
larized conditions in kinsenoside-containing medium
under Th1-inducing or Th2-inducing conditions. These
results indicate that kinsenoside upregulates the cell popu-
lation of CD4+CD25+ Tregs, thereby attenuating the
progression of CIA. Our analysis, conducted using flow cy-
tometry, demonstrated that the administration of kinseno-
side reduced the cell population of CD19+CD45+ and CD4
+Tim-3+, and increased the cell population of CD4+CD25+
cells in splenocytes. These results suggested that kinseno-
side downregulated Th1-cell response, thereby mediating
antiinflammatory functions. Kinsenoside might also indir-
ectly suppress Th1 response by increasing the number of
Tregs. However, the increase in the production of IL-10 in
splenocytes by kinsenoside is evidence against a shift to-
ward Th2 responses. However, the naïve CD4+ cells iso-
lated from healthy mice provided evidence that kinsenoside
did not influence Th1 or Th2 differentiation ex vivo. Ac-
cording to our previous data, kinsenoside was responsible
for the suppression of airway hyperresponsiveness in mice
who inhaled OVA through the modulation of Tregs [13].
Therefore, the inhibition of Th1 cytokines by using kinse-
noside is dependent of its action by modulating Tregs.
Tregs can also modulate monocyte function and directly
inhibit the immunoglobulin response of B cells [40]. Our
results demonstrated that kinsenoside enhanced the ex-
pression of Tregs, thereby decreasing the B cell population.
T-cell-dependent antigen B-cell responses exhibited similar
changes and were consistent with these findings. We dem-
onstrated that kinsenoside significantly reduced the levels
of CII-specific IgG1 and IgG2a Abs in the serum of mice
with RA. Kinsenoside treatment caused a deficiency in the
generation of deleterious autoimmune antibody responses,
suggesting that kinsenoside played an essential role in regu-
lating B cell trafficking and antibody production.
Conclusion
We confirmed that kinsenoside inhibits the inflammatory
mediator on RA in our in vivo study. Kinsenoside
effectively mitigated the destruction of cartilage and inflam-
matory responses in mice with CIA. These therapeutic ef-
fects partially resulted from the direct suppression of
MMP-9 production in the joints by inhibiting inflammatory
cytokines, including IL-1β and TNF-α. These results sug-
gest that kinsenoside inhibits the inflammatory mediator
release in a CIA induced arthritis mouse model by regulat-
ing the T cells responses.
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